Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes.

Zabrowski, Douglas; Abraham, Danielle; Rosenthal, Geoffrey; Kader, Howard

Zabrowski, Douglas; Abraham, Danielle; Rosenthal, Geoffrey; Kader, Howard.

Afiliação

Zabrowski D; Department of Pediatrics, Division of Pediatric Gastroenterology/Nutrition University of Maryland School of Medicine Baltimore Maryland USA.
Abraham D; Department of Epidemiology and Public Health University of Maryland School of Medicine Baltimore Maryland USA.
Rosenthal G; Department of Epidemiology and Public Health University of Maryland School of Medicine Baltimore Maryland USA.
Kader H; Department of Pediatrics, Division of Cardiology University of Maryland School of Medicine Baltimore Maryland USA.

JGH Open ; 4(4): 636-641, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32782950

Palavras-chave

adverse events; complications; eosinophilia; inflammatory bowel disease; infliximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article